找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Cell and Gene Therapies; Miguel-Angel Perales,Syed A. Abutalib,Catherine Bo Book 2019 Springer Nature Switzerland AG 2019 Chimeric antigen

[复制链接]
查看: 8285|回复: 54
发表于 2025-3-21 16:07:18 | 显示全部楼层 |阅读模式
书目名称Cell and Gene Therapies
编辑Miguel-Angel Perales,Syed A. Abutalib,Catherine Bo
视频video
概述Addresses key clinically relevant issues across the full spectrum of cell and gene therapies.Draws attention to the availability and implications of high-impact clinical trials.Assists trainee and pra
丛书名称Advances and Controversies in Hematopoietic Transplantation and Cell Therapy
图书封面Titlebook: Cell and Gene Therapies;  Miguel-Angel Perales,Syed A. Abutalib,Catherine Bo Book 2019 Springer Nature Switzerland AG 2019 Chimeric antigen
描述.In this book, experts in the field express their well-reasoned opinions on a range of complex, clinically relevant issues across the full spectrum of cell and gene therapies with the aim of providing trainee and practicing hematologists, including hematopoietic transplant physicians, with information that is relevant to clinical practice and ongoing research. Each chapter focuses on a particular topic, and the concise text is supported by numerous working tables, algorithms, and figures. Whenever appropriate, guidance is provided regarding the availability of potentially high-impact clinical trials. The rapid evolution of cell and gene therapies is giving rise to numerous controversies that need to be carefully addressed. In meeting this challenge, this book will appeal to all residents, fellows, and faculty members responsible for the care of hematopoietic cell transplant patients. It will also offer a robust, engaging tool to aid vital activities in the daily work of every hematology and oncology trainee..
出版日期Book 2019
关键词Chimeric antigen receptor-T cells; Cytotoxic T cells for infections; Tumor infiltrating lymphocytes; De
版次1
doihttps://doi.org/10.1007/978-3-319-54368-0
isbn_ebook978-3-319-54368-0Series ISSN 2569-1376 Series E-ISSN 2569-135X
issn_series 2569-1376
copyrightSpringer Nature Switzerland AG 2019
The information of publication is updating

书目名称Cell and Gene Therapies影响因子(影响力)




书目名称Cell and Gene Therapies影响因子(影响力)学科排名




书目名称Cell and Gene Therapies网络公开度




书目名称Cell and Gene Therapies网络公开度学科排名




书目名称Cell and Gene Therapies被引频次




书目名称Cell and Gene Therapies被引频次学科排名




书目名称Cell and Gene Therapies年度引用




书目名称Cell and Gene Therapies年度引用学科排名




书目名称Cell and Gene Therapies读者反馈




书目名称Cell and Gene Therapies读者反馈学科排名




单选投票, 共有 1 人参与投票
 

1票 100.00%

Perfect with Aesthetics

 

0票 0.00%

Better Implies Difficulty

 

0票 0.00%

Good and Satisfactory

 

0票 0.00%

Adverse Performance

 

0票 0.00%

Disdainful Garbage

您所在的用户组没有投票权限
发表于 2025-3-21 21:15:43 | 显示全部楼层
发表于 2025-3-22 03:02:14 | 显示全部楼层
Chimeric Antigen Receptor T Cells: Antigen Selection, CAR Development, and Data in Neoplastic Hematogen receptor T cells provide exciting potential for curative treatments to patients with cancers found intractable with current therapies. Toxicities are one of the main limiting factors for wide applicability of CAR-T-cell therapy. The major limiting adverse events include neurotoxicity and cytokin
发表于 2025-3-22 08:11:42 | 显示全部楼层
Chimeric Antigen Receptor T Cells for Leukemias in Children: Methods, Data, and Challengesacute lymphoblastic leukemia (ALL) and 50–60% with acute myeloid leukemia (AML) experience long-term disease control after multimodal treatments that often include intensified chemotherapy. Relapsed leukemia patients pose a challenging subset of the pediatric leukemic population due to highly resist
发表于 2025-3-22 11:41:29 | 显示全部楼层
发表于 2025-3-22 14:47:34 | 显示全部楼层
Chimeric Antigen Receptor T Cells for Lymphomas: Methods, Data, and Challengesll lymphocytic lymphoma (CLL/SLL) and B-cell acute lymphoblastic leukemia (B-ALL). However, targeting CD19 can result in prolonged B-cell aplasia. Given the clinical experience with the anti-CD20 monoclonal antibody rituximab with temporary B-cell aplasia, severe clinical consequence has not been ob
发表于 2025-3-22 18:40:20 | 显示全部楼层
T Cell Receptors-Gene-Modified T Cells for Cancer: Methods, Data, and Challengeslogy and new developments in synthetic biology have led to an ability to engineer T cells to express antibody-like recognition molecules linked to T cell-activating domains (chimeric antigen receptors, CARs) and tumor-specific T cell receptors (TCRs) which redirect patient-derived T cells toward the
发表于 2025-3-23 00:32:44 | 显示全部楼层
发表于 2025-3-23 05:07:46 | 显示全部楼层
发表于 2025-3-23 05:58:07 | 显示全部楼层
Natural Killer Cells: What Have We Learned?of the potential of immunotherapy as a therapeutic strategy. In recent years, such skepticism has diminished significantly as clinical evidence increasingly demonstrates the effectiveness of manipulating the immune system to treat a variety of established tumors. Among components of the immune syste
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-2 20:52
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表